X
- No products in the list
The UltraSEEK Lung Panel enables accurate detection of lung cancer variants in circulating free DNA (cfDNA), offering a non-invasive, highly sensitive approach to mutation profiling in non-small cell lung cancer (NSCLC). With detection of over 70 variants across BRAF, EGFR, ERBB2, KRAS, and PIK3CA, this research-use-only (RUO) panel supports disease progression studies and resistance monitoring from a single blood draw. Requiring only 10 ng of cfDNA and detecting down to 0.1% variant allele frequency (VAF), the UltraSEEK Lung Panel is optimized for use with low-quality DNA samples and helps reduce rejection rates often seen with sequencing-based workflows.
The UltraSEEK® Lung Panel is a focused mutation detection assay for studying non-small cell lung cancer (NSCLC) through cfDNA-based liquid biopsy. Covering more than 70 mutations across five essential lung cancer genes—BRAF, EGFR, ERBB2, KRAS, and PIK3CA—this panel enables high-sensitivity analysis of actionable biomarkers that drive disease initiation, progression, and resistance to therapy.
With just 10 ng of input cfDNA, the panel supports research on tumor evolution and resistance acquisition, including after TKI treatment. Unlike traditional sequencing workflows, this assay is designed to work with degraded or low-concentration samples, increasing the number of usable specimens in clinical studies.
Lung cancer, particularly NSCLC, is often driven by mutations in genes involved in cell growth signaling pathways. Mutations in EGFR (e.g., exon 19 deletions or exon 20 insertions), KRAS (e.g., codon 12 or 13), and BRAF are clinically relevant and frequently used to guide treatment decisions with targeted inhibitors.
However, resistance often develops—e.g., EGFR T790M mutations or ERBB2 insertions—necessitating ongoing monitoring. Traditional tissue biopsies are invasive and do not always capture the full heterogeneity of tumor mutations. The use of cfDNA for lung variant detection allows researchers to non-invasively monitor tumor dynamics in real time and adjust treatment strategies accordingly.
The UltraSEEK Lung Panel detects variants with high sensitivity and specificity using Agena’s proprietary mass spectrometry technology. The panel can be applied to cfDNA from plasma and is suitable for longitudinal studies, clinical trials, and translational research in NSCLC.
Gene coverage includes: See variant list
By targeting mutation hotspots relevant to NSCLC treatment response and resistance, the panel ensures deep insight into patient-specific tumor profiles.
The UltraSEEK Lung Panel utilizes a multiplex PCR strategy followed by single base extension and detection via mass spectrometry. This streamlined workflow minimizes handling and maximizes consistency, reducing the burden on lab resources.
Workflow Overview:
cfDNA extraction from patient plasma
PCR amplification of targeted lung cancer loci
Single base extension to distinguish variants
Mass spectrometry analysis
Variant calling and reporting via integrated software
This approach is optimized for sensitivity, detecting mutations at VAFs as low as 0.1%, far below most sequencing-based cutoff thresholds.
While the UltraSEEK Lung Panel is intended for research use only, it mirrors many clinical workflows used in NSCLC molecular diagnostics. Researchers studying resistance to tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, or combination therapies can benefit from this assay’s sensitivity and multiplexing capabilities.
The panel is particularly valuable in scenarios where biopsy tissue is limited, unavailable, or insufficient in quality. By enabling detection of lung-specific variants from cfDNA, it empowers researchers to conduct comprehensive mutation tracking and resistance profiling with minimal sample requirements and fewer rejections due to low DNA yield.
Brochure
For any missing information or if you require additional details, please do not hesitate to contact us.